Free Trial
→ Trump’s issues shocking Executive Order on U.S. Dollar (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:OCS

Oculis Q3 2026 Earnings Date & Estimates

Oculis logo
$8.34 -0.32 (-3.70%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$8.36 +0.02 (+0.24%)
As of 10/9/2026 06:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Oculis is expected to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for November 3, 2026 at 12:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
12:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Oculis in Q3 2026

Oculis is expected to post earnings of -$0.49 per share on revenue of $0.25 million. In the same quarter a year earlier Oculis reported -$0.40 per share on revenue of $0.31 million. Oculis last reported on August 6, 2026, posting -$0.20 per share and beating the -$0.48 consensus estimate. Oculis has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.49
Expected Revenue
$0.25 million
Prior-Year EPS
-$0.40
Prior-Year Revenue
$0.31 million
Expected Revenue Growth
-19.0%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.20 (Beat by +$0.28)
Last Quarter Revenue
$0.38 million
EPS Beat Rate
2 of last 8 quarters

Prepare for the Q3 2026 Call

Oculis Q3 2026 Earnings FAQ

Oculis (NASDAQ:OCS) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Oculis' Q3 2026 earnings conference call is scheduled for Tuesday, November 3, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Oculis to post earnings of -$0.49 per share for Q3 2026.

The consensus revenue estimate for Oculis is $0.25 million for Q3 2026.

Oculis Earnings Headlines

Oculis to Present Licaminlimab Precision Medicine Data at AAO 2026 Ahead of Year-End PREDICT-1 Readout
October 7 at 2:10 AM  |  quiverquant.comQ
Oculis to Present Licaminlimab Precision Medicine Approach for Dry Eye Disease at AAO 2026, PREDICT-1 Topline Readout Expected by Year-End
October 7 at 2:10 AM  |  quiverquant.comQ
Elon just declared war on your phone
SpaceX reportedly agreed to pay 8 billion dollars for a major slice of U.S. wireless spectrum, and shares of AT&T, Verizon, and T-Mobile dropped within hours of the news. Elon Musk called the deal the last critical piece for complete phone coverage in America, fueling speculation about a future device that could challenge the iPhone.tc pixel
October 10 at 1:00 AM  |  Stansberry Research (Ad)
Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day
October 7 at 2:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/07/3376181/0/en/oculis-to-highlight-licaminlimab-at-eyecelerator-aao-2026-and-partner-with-neuro-ophthalmology-subspecialty-day.html
Oculis (NASDAQ:OCS) Stock Falls 5.6% - Here's Why
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31082733
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
October 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/01/3372528/0/en/oculis-joins-the-national-multiple-sclerosis-society-s-campaign-to-end-ms.html
See More Oculis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oculis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oculis and other key companies, straight to your email.

About Oculis

Oculis (NASDAQ:OCS) (NASDAQ: OCS) is a biopharmaceutical company focused on developing and commercializing innovative treatments for eye diseases. The company aims to address significant unmet needs in ophthalmology through therapies designed for topical, noninvasive administration and other targeted delivery approaches.

Oculis’ pipeline has included OCS-01, a topical dexamethasone formulation being developed for retinal diseases such as diabetic macular edema, and licaminlimab (OCS-02), an ophthalmic anti-TNF biologic being investigated for conditions including dry eye disease. The company has also pursued OCS-05, an investigational neuroprotective therapy for disorders affecting the optic nerve and retina. Pipeline programs and development priorities may change as clinical research progresses.

Founded in Switzerland, Oculis has developed its programs for international markets and conducts research and clinical activities across multiple regions. The company became publicly listed on Nasdaq in 2023 following a business combination with European Biotech Acquisition Corp. Oculis is led by Chief Executive Officer Riad Sherif, M.D.

View Oculis Profile
Earnings Tools